HUE044180T2 - Biciklusos kondenzált heteroaril- vagy aril-vegyületek és ezek alkalmazása IRAK4 inhibitorokként - Google Patents

Biciklusos kondenzált heteroaril- vagy aril-vegyületek és ezek alkalmazása IRAK4 inhibitorokként

Info

Publication number: HUE044180T2
Authority: HU; Hungary
Prior art keywords: bicyclic; fused heteroaryl; aryl compounds; irak4 inhibitors; irak4
Prior art date: 2014-04-04

Application number

Other languages

English (en)

Inventor

David Randolph Anderson

Mark Edward Bunnage

Kevin Joseph Curran

Christoph Martin Dehnhardt

Lori Krim Gavrin

Joel Adam Goldberg

Seungil Han

David Hepworth

Horng-Chih Huang

Arthur Lee

Katherine Lin Lee

Frank Eldridge Lovering

Michael Dennis Lowe

John Paul Mathias

Nikolaos Papaioannou

Akshay Patny

Betsy Susan Pierce

Eddine Saiah

Joseph Walter Strohbach

John David Trzupek

Richard Vargas

Xiaolun Wang

Stephen Wayne Wright

Christoph Wolfgang Zapf

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-04-04

Filing date

2015-03-26

Publication date

2019-10-28

2015-03-26 Application filed by Pfizer filed Critical Pfizer

2019-10-28 Publication of HUE044180T2 publication Critical patent/HUE044180T2/hu

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/66—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems and singly-bound oxygen atoms, bound to the same carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
- C07C69/94—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of polycyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of six-membered aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/267—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Neurology (AREA)
Hematology (AREA)
Physical Education & Sports Medicine (AREA)
Immunology (AREA)
Communicable Diseases (AREA)
Cardiology (AREA)
Ophthalmology & Optometry (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Orthopedic Medicine & Surgery (AREA)
Obesity (AREA)
Dermatology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Oncology (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Pyrrole Compounds (AREA)

HUE15717250 2014-04-04 2015-03-26 Biciklusos kondenzált heteroaril- vagy aril-vegyületek és ezek alkalmazása IRAK4 inhibitorokként HUE044180T2 (hu)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201461975473P	2014-04-04	2014-04-04

Publications (1)

Publication Number	Publication Date
HUE044180T2 true HUE044180T2 (hu)	2019-10-28

Family

ID=52988358

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
HUE19157789A HUE057876T2 (hu)	2014-04-04	2015-03-26	Biciklusos-kondenzált heteroaril- vagy aril-vegyületek és ezek IRAK4 inhibitorként történõ alkalmazása
HUE15717250 HUE044180T2 (hu)	2014-04-04	2015-03-26	Biciklusos kondenzált heteroaril- vagy aril-vegyületek és ezek alkalmazása IRAK4 inhibitorokként

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
HUE19157789A HUE057876T2 (hu)	2014-04-04	2015-03-26	Biciklusos-kondenzált heteroaril- vagy aril-vegyületek és ezek IRAK4 inhibitorként történõ alkalmazása

Country Status (46)

Country	Link
US (6)	US9458168B2 (hu)
EP (2)	EP3536685B1 (hu)
JP (2)	JP6177456B2 (hu)
KR (1)	KR101901044B1 (hu)
CN (1)	CN106458912B (hu)
AP (1)	AP2016009514A0 (hu)
AR (1)	AR099955A1 (hu)
AU (1)	AU2015242291B2 (hu)
BR (1)	BR112016023117B1 (hu)
CA (1)	CA2944475C (hu)
CL (1)	CL2016002524A1 (hu)
CR (1)	CR20160456A (hu)
CU (1)	CU24406B1 (hu)
CY (2)	CY1121694T1 (hu)
DK (2)	DK3126330T3 (hu)
DO (1)	DOP2016000271A (hu)
EA (1)	EA032559B1 (hu)
EC (1)	ECSP16076566A (hu)
ES (2)	ES2910128T3 (hu)
GE (1)	GEP20186887B (hu)
GT (1)	GT201600215A (hu)
HR (2)	HRP20220362T1 (hu)
HU (2)	HUE057876T2 (hu)
IL (1)	IL248158B (hu)
LT (2)	LT3536685T (hu)
MA (2)	MA52856B1 (hu)
MD (1)	MD4779B1 (hu)
ME (1)	ME03599B (hu)
MX (1)	MX2016013052A (hu)
MY (1)	MY192521A (hu)
NI (1)	NI201600152A (hu)
NZ (1)	NZ724578A (hu)
PE (1)	PE20161251A1 (hu)
PH (1)	PH12016501972A1 (hu)
PL (2)	PL3126330T3 (hu)
PT (2)	PT3536685T (hu)
RS (2)	RS63024B1 (hu)
SG (1)	SG11201608110WA (hu)
SI (2)	SI3126330T1 (hu)
SV (1)	SV2016005295A (hu)
TR (1)	TR201904658T4 (hu)
TW (3)	TWI593683B (hu)
UA (1)	UA121467C2 (hu)
UY (1)	UY36056A (hu)
WO (1)	WO2015150995A1 (hu)
ZA (1)	ZA201606550B (hu)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL3321359T3 (pl)	2005-04-11	2021-06-28	Horizon Pharma Rheumatology Llc	Wariantowe postacie oksydazy moczanowej i ich zastosowanie
HUP1200205A3 (en)	2009-06-25	2012-09-28	Savient Pharmaceuticals	Method and kits for perdicting infusion reaction risk and antibody-mediated low of response by monitoring serum uric acid during pegylated uricare therapy
CN103298792A (zh)	2010-11-19	2013-09-11	利亘制药公司	杂环胺及其用途
GB201311891D0 (en)	2013-07-03	2013-08-14	Glaxosmithkline Ip Dev Ltd	Novel compound
GB201311888D0 (en)	2013-07-03	2013-08-14	Glaxosmithkline Ip Dev Ltd	Novel compounds
GEP20186920B (en)	2014-04-04	2018-11-12	Lundbeck A/S H	Halogenated quinazolinthf-amines as pde1 inhibitors
RS63024B1 (sr) *	2014-04-04	2022-04-29	Pfizer	Kondenzovana biciklična heteroaril ili aril jedinjenja i njihova upotreba kao irak4 inhibitora
BR112018002071A2 (pt)	2015-08-13	2018-09-18	Pfizer	compostos heteroarílicos ou arílicos fundidos bicíclicos
KR102029124B1 (ko) *	2015-08-27	2019-10-07	화이자 인코포레이티드	Irak4 조정제로서의 비시클릭-융합된 헤테로아릴 또는 아릴 화합물
WO2018026877A1 (en)	2016-08-05	2018-02-08	Calitor Sciences, Llc	Process for preparing substituted quinolin-4-ol compounds
US11254667B2 (en)	2016-08-17	2022-02-22	Children's Hospital Medical Center	Substituted imidazo[1,2-A]pyridines as IRAK 1/4 and flt3 inhibitors
US11542261B2 (en)	2016-08-17	2023-01-03	Children's Hospital Medical Center	Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors
AU2017341825B2 (en) *	2016-10-13	2023-06-01	Travere Therapeutics, Inc.	Biphenyl sulfonamide compounds for the treatment of kidney diseases or disorders
KR20180066296A (ko) *	2016-12-07	2018-06-19	서울대학교산학협력단	토파시티닙을 포함하는 고염증 증상의 예방 또는 치료용 약학적 조성물 및 토파시티닙을 포함하는 고염증 증상의 예방 또는 개선용 건강기능식품 조성물
JOP20180011A1 (ar)	2017-02-16	2019-01-30	Gilead Sciences Inc	مشتقات بيرولو [1، 2-b]بيريدازين
CA3062602A1 (en)	2017-05-11	2018-11-15	Bristol-Myers Squibb Company	Thienopyridines and benzothiophenes useful as irak4 inhibitors
CN108558854A (zh) *	2017-06-10	2018-09-21	曹艳	一种治疗革兰氏阳性菌引起的感染的药物及其合成方法
GB201712282D0 (en) *	2017-07-31	2017-09-13	Nodthera Ltd	Selective inhibitors of NLRP3 inflammasome
EP3684365A4 (en)	2017-09-22	2021-09-08	Kymera Therapeutics, Inc.	PROTEIN DEGRADATION AGENTS AND USES OF SUCH
WO2019060693A1 (en)	2017-09-22	2019-03-28	Kymera Therapeutics, Inc.	CRBN LIGANDS AND USES THEREOF
IL310346A (en)	2017-10-20	2024-03-01	Univ Vanderbilt	Muscarinic acetylcholine M4 receptor antagonists
US20200385370A1 (en)	2017-10-30	2020-12-10	Synblia Therapeutics, Inc.	Apparatus for removing bad odor from toilet
EP3703680B1 (en)	2017-10-31	2024-05-15	Vanderbilt University	Antagonists of the muscarinic acetylcholine receptor m4
WO2019099926A1 (en)	2017-11-17	2019-05-23	Arvinas, Inc.	Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
WO2019111218A1 (en)	2017-12-08	2019-06-13	Cadila Healthcare Limited	Novel heterocyclic compounds as irak4 inhibitors
EP3731869A4 (en)	2017-12-26	2021-09-22	Kymera Therapeutics, Inc.	KINASES IRAQ DEGRADATION AGENTS AND THEIR USES
WO2019140387A1 (en)	2018-01-12	2019-07-18	Kymera Therapeutics, Inc.	Crbn ligands and uses thereof
WO2019140380A1 (en)	2018-01-12	2019-07-18	Kymera Therapeutics, Inc.	Protein degraders and uses thereof
JP7316288B2 (ja) *	2018-01-31	2023-07-27	メルクパテントゲゼルシャフトミットベシュレンクテルハフツング	Ｉｒａｋ阻害剤としてのキノリン化合物及びその使用
KR20200116945A (ko)	2018-02-02	2020-10-13	반더빌트유니버시티	무스카린성 아세틸콜린 수용체 m4의 길항제
PE20210640A1 (es)	2018-02-13	2021-03-23	Gilead Sciences Inc	Inhibidores pd-1/pd-l1
US11542251B2 (en) *	2018-02-14	2023-01-03	Dana-Farber Cancer Institute, Inc.	IRAK degraders and uses thereof
CN108299397B (zh) *	2018-03-21	2019-01-29	佳木斯大学附属第一医院	一种用于降血压的活性药物及其制备方法
JP7242702B2 (ja)	2018-04-19	2023-03-20	ギリアードサイエンシーズ，インコーポレイテッド	Ｐｄ－１／ｐｄ－ｌ１阻害剤
EP3810144A4 (en) *	2018-06-04	2022-08-17	Chemistryrx	TOPICAL HAIR GROWTH STIMULATING COMPOSITIONS
US11292792B2 (en)	2018-07-06	2022-04-05	Kymera Therapeutics, Inc.	Tricyclic CRBN ligands and uses thereof
TWI721483B (zh)	2018-07-13	2021-03-11	美商基利科學股份有限公司	吡咯并[1,2-b]嗒𠯤衍生物
CN109147870A (zh) *	2018-07-26	2019-01-04	刘滨	基于条件随机场的固有无序蛋白质的识别方法
TWI727392B (zh)	2018-08-13	2021-05-11	美商基利科學股份有限公司	噻二唑irak4抑制劑
JP7169429B2 (ja)	2018-08-13	2022-11-10	ギリアードサイエンシーズ，インコーポレイテッド	ＩＲＡＫ４阻害剤としてのピロロ［１，２－ｂ］ピリダジン誘導体
CA3105558C (en)	2018-08-13	2023-09-26	Gilead Sciences, Inc.	Pyrrolo[1,2-b]pyridazine derivatives as irak4 inhibitors
US11352350B2 (en)	2018-11-30	2022-06-07	Kymera Therapeutics, Inc.	IRAK degraders and uses thereof
DE102018221954A1 (de) *	2018-12-17	2020-06-18	Robert Bosch Gmbh	Recheneinrichtung und Verfahren zum Betreiben einer Recheneinrichtung
WO2020160322A1 (en) *	2019-01-30	2020-08-06	Horizon Pharma Rheumatology Llc	Tolerization reduces intolerance to pegloticase and prolongs the urate lowering effect (triple)
CN111662295B (zh) *	2019-03-05	2021-09-10	珠海宇繁生物科技有限责任公司	一种irak4激酶抑制剂及其制备方法
KR102289661B1 (ko) *	2019-05-15	2021-08-17	가톨릭대학교 산학협력단	요산분해효소를 과발현하는 줄기세포를 유효성분으로 포함하는 통풍의 예방 또는 치료용 조성물
US20220281844A1 (en) *	2019-08-06	2022-09-08	Bristol-Myers Squibb Company	Bicyclic heterocyclic compounds useful as irak4 inhibitors
CN112679472A (zh) *	2019-10-17	2021-04-20	北京桦冠医药科技有限公司	具有irak4抑制剂活性的异喹啉类化合物
MX2022005882A (es)	2019-11-14	2022-06-14	Pfizer	Combinaciones de 1-(((2s,3s,4s)-3-etil-4-fluoro-5-oxopirrolidin-2- il)metoxi)-7-metoxiisoquinolin-6-carboxamida y formas de dosis orales.
US20210154292A1 (en) *	2019-11-21	2021-05-27	Chemocentryx, Inc.	Compositions and Methods for Treating CCR9-Mediated Diseases using CCR9 Inhibitor and Anti-TNF-Alpha Blocking Antibodies
CA3161878A1 (en)	2019-12-17	2021-06-24	Matthew M. Weiss	Irak degraders and uses thereof
EP4076524A4 (en)	2019-12-17	2023-11-29	Kymera Therapeutics, Inc.	IRAQ DEGRADERS AND USES THEREOF
US20230095341A1 (en) *	2020-01-29	2023-03-30	Georgetown University	Compositions and methods for treating neurodegenerative, myodegenerative, and lysosomal storage disorders
EP4125900A1 (en)	2020-04-04	2023-02-08	Pfizer Inc.	Methods of treating coronavirus disease 2019
TW202210483A (zh)	2020-06-03	2022-03-16	美商凱麥拉醫療公司	Irak降解劑之結晶型
EP4223368A4 (en)	2020-09-30	2024-06-19	Asahi Kasei Pharma Corporation	MACROCYCLIC COMPOUND
CA3194164A1 (en)	2020-09-30	2022-04-07	Koichiro Arai	Pyrimidine- and nitrogen-containing bicyclic compound
US11866405B2 (en)	2020-12-10	2024-01-09	Astrazeneca Ab	Substituted indazoles as IRAK4 inhibitors
IL312397A (en) *	2021-10-29	2024-06-01	Kymera Therapeutics Inc	IRAK4 subunits and their synthesis
WO2023152349A1 (en)	2022-02-14	2023-08-17	Astrazeneca Ab	Irak4 inhibitors
US11618751B1 (en)	2022-03-25	2023-04-04	Ventus Therapeutics U.S., Inc.	Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US20230312568A1 (en)	2022-03-31	2023-10-05	Rigel Pharmaceuticals, Inc.	Tricyclic irak inhibitors
WO2023227703A1 (en)	2022-05-26	2023-11-30	Astrazeneca Ab	Solid forms of heterocyclylamides as irak4 inhibitors
WO2023235433A1 (en) *	2022-06-01	2023-12-07	Rigel Pharmaceuticals, Inc.	Bicyclic inhibitors of irak

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3673238A (en) *	1970-02-10	1972-06-27	Usv Pharma Corp	2-naphthoic acid derivatives
EP0028489B1 (en)	1979-11-05	1983-10-05	Beecham Group Plc	Enzyme derivatives, and their preparation
EP0313943B1 (en)	1987-10-20	1993-08-04	MITSUI TOATSU CHEMICALS, Inc.	1,2-naphtalocyanine near-infrared absorbent and recording/display materials using same
US4861795A (en) *	1988-06-23	1989-08-29	Rorer Pharmaceutical Corporation	Treatment of conditions requiring enhanced oxygen availability to mammalian tissues
JP2671059B2 (ja) *	1990-11-30	1997-10-29	富士レビオ株式会社	ナフトエ酸誘導体
JPH05148222A (ja)	1991-11-29	1993-06-15	Fujirebio Inc	ナフトエ酸誘導体
US5837689A (en) *	1993-06-16	1998-11-17	Glycomed Incorporated	Sialyl lewis-x mimetics containing naphthyl backbones
AU686691B2 (en)	1994-01-12	1998-02-12	F. Hoffmann-La Roche Ag	Novel azepanes and homologs thereof
US5612359A (en)	1994-08-26	1997-03-18	Bristol-Myers Squibb Company	Substituted biphenyl isoxazole sulfonamides
TR199600329A2 (tr)	1995-05-05	1997-03-21	Hoffmann La Roche	Seker alkollerin yeni sülfürik asit esterleri.
GB9514265D0 (en) *	1995-07-13	1995-09-13	Wellcome Found	Hetrocyclic compounds
TW536540B (en)	1997-01-30	2003-06-11	Bristol Myers Squibb Co	Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
PL203771B1 (pl)	1998-07-06	2009-11-30	Bristol Myers Squibb Co	Pochodna bifenylosulfonamidu jako dualny antagonista receptorów angiotensyny i endoteliny, sposób jej wytwarzania i jej zastosowanie oraz pochodna bifenylu i pochodna benzenu
CN1360582A (zh) *	1999-07-07	2002-07-24	阿斯特拉曾尼卡英国有限公司	喹唑啉衍生物
MY125533A (en)	1999-12-06	2006-08-30	Bristol Myers Squibb Co	Heterocyclic dihydropyrimidine compounds
ES2282299T3 (es) *	2000-10-20	2007-10-16	EISAI R&D MANAGEMENT CO., LTD.	Compuestos aromaticos con anillos de nitrogeno como agentes anticancerigenos.
IL163659A0 (en)	2002-02-27	2005-12-18	Pfizer Prod Inc	Acc inhibitors
JPWO2005080377A1 (ja) *	2004-02-20	2007-10-25	キリンホールディングス株式会社	ＴＧＦβ阻害活性を有する化合物およびそれを含んでなる医薬組成物
PT1753748E (pt)	2004-05-12	2009-08-28	Pfizer Prod Inc	Derivados de prolina e a sua utilização como inibidores de dipeptidil peptidase iv
CA2612260C (en)	2005-07-07	2013-10-29	Abbott Laboratories	Apoptosis promoters
US7572809B2 (en)	2005-12-19	2009-08-11	Hoffmann-La Roche Inc.	Isoquinoline aminopyrazole derivatives
DK2463283T3 (da)	2006-04-20	2014-08-18	Pfizer Prod Inc	Kondenserede heterocykliske phenylamidoforbindelser til forebyggelse og behandling af glucokinase-medierede sygdomme
MX2009005604A (es)	2006-11-29	2009-06-08	Pfizer Prod Inc	Inhibidores espiro cetona de acetil-coa carboxilasa.
US9623021B2 (en)	2007-01-22	2017-04-18	Gtx, Inc.	Nuclear receptor binding agents
CN101641013B (zh)	2007-01-22	2014-07-30	Gtx公司	核受体结合剂
WO2008103354A2 (en)	2007-02-20	2008-08-28	Cropsolution, Inc.	Modulators of acetyl-coenzyme a carboxylase and methods of use thereof
US20090023773A1 (en)	2007-06-27	2009-01-22	Painceptor Pharma Corporation	Compositions and methods for modulating gated ion channels
US20090036425A1 (en)	2007-08-02	2009-02-05	Pfizer Inc	Substituted bicyclolactam compounds
CN101245022A (zh) *	2008-03-21	2008-08-20	东华大学	3,5-双(2,4-二氨基苯氧基)-2-萘甲酸的制备方法
WO2009144555A1 (en)	2008-05-28	2009-12-03	Pfizer Inc.	Pyrazolospiroketone acetyl-coa carboxylase inhibitors
EP2297163B1 (en)	2008-05-28	2015-07-08	Pfizer Inc.	Pyrazolospiroketone acetyl-CoA carboxylase inhibitors
DE102008027574A1 (de)	2008-06-10	2009-12-17	Merck Patent Gmbh	Neue Pyrrolidinderivate als MetAP-2 Inhibitoren
CN101353307A (zh) *	2008-07-25	2009-01-28	东华大学	3,5-双(2,6-二硝基-4-三氟甲基苯氧基)-2-萘甲酸的制备方法
EP2318370A1 (en)	2008-07-29	2011-05-11	Pfizer Inc.	Fluorinated heteroaryls
CN103497199B (zh)	2008-08-28	2015-04-29	辉瑞大药厂	二氧杂-双环[3.2.1]辛烷-2,3,4-三醇衍生物
TW201038580A (en)	2009-02-02	2010-11-01	Pfizer	4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives
EA018894B1 (ru)	2009-03-11	2013-11-29	Пфайзер Инк.	N,n-диметил-5-(2-метил-6-((5-метилпиразин-2-ил)карбамоил)бензо-фуран-4-илокси)пиримидин-2-карбоксамид, используемый в качестве активатора глюкокиназы, и содержащая его фармацев-тическая композиция
WO2010103438A1 (en)	2009-03-11	2010-09-16	Pfizer Inc.	Substituted indazole amides and their use as glucokinase activators
EP2408780A2 (en)	2009-03-20	2012-01-25	Pfizer Inc.	3-oxa-7-azabicycloý3.3.1¨nonanes
JP2012526096A (ja)	2009-05-08	2012-10-25	ファイザー・インク	Ｇｐｒ１１９調節因子
WO2010128425A1 (en)	2009-05-08	2010-11-11	Pfizer Inc.	Gpr 119 modulators
AP2799A (en)	2009-06-05	2013-11-30	Pfizer	1-(Piperidin-4-YL)-pyrazole derivatives as GPR 119modulators
WO2011005611A1 (en)	2009-07-09	2011-01-13	Merck Sharp & Dohme Corp.	Neuromedin u receptor agonists and uses thereof
WO2011153553A2 (en)	2010-06-04	2011-12-08	The Regents Of The University Of California	Methods and compositions for kinase inhibition
WO2011159781A2 (en)	2010-06-17	2011-12-22	Senomyx, Inc.	Bitter taste modulators
CN103827090B (zh)	2011-07-26	2016-04-20	勃林格殷格翰国际有限公司	取代的喹啉及其作为药物的用途
WO2013142390A1 (en)	2012-03-21	2013-09-26	Gtx, Inc.	Aldo-keto reductase subfamily 1c3 (akr1c3) inhibitors
WO2014039820A1 (en)	2012-09-07	2014-03-13	Gtx, Inc.	Aldo-keto reductase subfamily 1c3 (akr1c3) inhibitors
MX2016001427A (es)	2013-07-31	2016-08-03	Gilead Sciences Inc	Inhibidores de syk.
RS63024B1 (sr) *	2014-04-04	2022-04-29	Pfizer	Kondenzovana biciklična heteroaril ili aril jedinjenja i njihova upotreba kao irak4 inhibitora
KR102029124B1 (ko) *	2015-08-27	2019-10-07	화이자 인코포레이티드	Irak4 조정제로서의 비시클릭-융합된 헤테로아릴 또는 아릴 화합물

2015
- 2015-03-26 RS RS20220257A patent/RS63024B1/sr unknown
- 2015-03-26 ES ES19157789T patent/ES2910128T3/es active Active
- 2015-03-26 EP EP19157789.9A patent/EP3536685B1/en active Active
- 2015-03-26 ME MEP-2019-113A patent/ME03599B/me unknown
- 2015-03-26 EA EA201600622A patent/EA032559B1/ru unknown
- 2015-03-26 TR TR2019/04658T patent/TR201904658T4/tr unknown
- 2015-03-26 BR BR112016023117-1A patent/BR112016023117B1/pt active IP Right Grant
- 2015-03-26 KR KR1020167030630A patent/KR101901044B1/ko active IP Right Grant
- 2015-03-26 SI SI201530676T patent/SI3126330T1/sl unknown
- 2015-03-26 JP JP2016560419A patent/JP6177456B2/ja active Active
- 2015-03-26 PT PT191577899T patent/PT3536685T/pt unknown
- 2015-03-26 LT LTEP19157789.9T patent/LT3536685T/lt unknown
- 2015-03-26 ES ES15717250T patent/ES2718552T3/es active Active
- 2015-03-26 SI SI201531825T patent/SI3536685T1/sl unknown
- 2015-03-26 PT PT15717250T patent/PT3126330T/pt unknown
- 2015-03-26 MA MA52856A patent/MA52856B1/fr unknown
- 2015-03-26 PL PL15717250T patent/PL3126330T3/pl unknown
- 2015-03-26 HU HUE19157789A patent/HUE057876T2/hu unknown
- 2015-03-26 PL PL19157789T patent/PL3536685T3/pl unknown
- 2015-03-26 DK DK15717250.3T patent/DK3126330T3/en active
- 2015-03-26 PE PE2016001905A patent/PE20161251A1/es unknown
- 2015-03-26 NZ NZ724578A patent/NZ724578A/en unknown
- 2015-03-26 DK DK19157789.9T patent/DK3536685T3/da active
- 2015-03-26 CR CR20160456A patent/CR20160456A/es unknown
- 2015-03-26 MD MDA20160106A patent/MD4779B1/ro not_active IP Right Cessation
- 2015-03-26 MA MA39838A patent/MA39838B1/fr unknown
- 2015-03-26 MX MX2016013052A patent/MX2016013052A/es active IP Right Grant
- 2015-03-26 GE GEAP201514288A patent/GEP20186887B/en unknown
- 2015-03-26 SG SG11201608110WA patent/SG11201608110WA/en unknown
- 2015-03-26 WO PCT/IB2015/052251 patent/WO2015150995A1/en active Application Filing
- 2015-03-26 MY MYPI2016703626A patent/MY192521A/en unknown
- 2015-03-26 CA CA2944475A patent/CA2944475C/en active Active
- 2015-03-26 HR HRP20220362TT patent/HRP20220362T1/hr unknown
- 2015-03-26 UA UAA201610113A patent/UA121467C2/uk unknown
- 2015-03-26 AP AP2016009514A patent/AP2016009514A0/en unknown
- 2015-03-26 LT LTEP15717250.3T patent/LT3126330T/lt unknown
- 2015-03-26 CN CN201580029784.3A patent/CN106458912B/zh active Active
- 2015-03-26 AU AU2015242291A patent/AU2015242291B2/en active Active
- 2015-03-26 CU CU2016000149A patent/CU24406B1/es unknown
- 2015-03-26 HU HUE15717250 patent/HUE044180T2/hu unknown
- 2015-03-26 RS RS20190450A patent/RS58597B1/sr unknown
- 2015-03-26 EP EP15717250.3A patent/EP3126330B1/en active Active
- 2015-03-27 UY UY0001036056A patent/UY36056A/es not_active Application Discontinuation
- 2015-04-01 AR ARP150101019A patent/AR099955A1/es unknown
- 2015-04-02 TW TW104111016A patent/TWI593683B/zh active
- 2015-04-02 TW TW106105786A patent/TWI623530B/zh active
- 2015-04-02 TW TW105117087A patent/TWI580678B/zh active
- 2015-04-03 US US14/678,114 patent/US9458168B2/en active Active
2016
- 2016-08-10 US US15/232,892 patent/US9879022B2/en active Active
- 2016-09-22 ZA ZA2016/06550A patent/ZA201606550B/en unknown
- 2016-09-26 EC ECIEPI201676566A patent/ECSP16076566A/es unknown
- 2016-09-29 IL IL248158A patent/IL248158B/en active IP Right Grant
- 2016-09-30 SV SV2016005295A patent/SV2016005295A/es unknown
- 2016-10-03 DO DO2016000271A patent/DOP2016000271A/es unknown
- 2016-10-03 NI NI201600152A patent/NI201600152A/es unknown
- 2016-10-04 CL CL2016002524A patent/CL2016002524A1/es unknown
- 2016-10-04 PH PH12016501972A patent/PH12016501972A1/en unknown
- 2016-10-04 GT GT201600215A patent/GT201600215A/es unknown
2017
- 2017-07-11 JP JP2017135751A patent/JP6492128B2/ja active Active
2018
- 2018-01-05 US US15/862,691 patent/US10329302B2/en active Active
2019
- 2019-03-13 HR HRP20190506TT patent/HRP20190506T1/hr unknown
- 2019-04-12 CY CY20191100413T patent/CY1121694T1/el unknown
- 2019-05-14 US US16/411,679 patent/US10793579B2/en active Active
2020
- 2020-08-18 US US16/996,117 patent/US11702424B2/en active Active
2022
- 2022-03-31 CY CY20221100251T patent/CY1125110T1/el unknown
2023
- 2023-06-28 US US18/342,977 patent/US20230339960A1/en active Pending

Also Published As

Publication number	Publication date
ES2718552T3 (es)	2019-07-02
TR201904658T4 (tr)	2019-04-22
MD20160106A2 (ro)	2017-03-31
PL3126330T3 (pl)	2019-09-30
PE20161251A1 (es)	2016-11-30
PH12016501972B1 (en)	2016-12-19
RS58597B1 (sr)	2019-05-31
CA2944475A1 (en)	2015-10-08
EP3536685A1 (en)	2019-09-11
TW201540707A (zh)	2015-11-01
LT3126330T (lt)	2019-04-25
WO2015150995A1 (en)	2015-10-08
MA52856B1 (fr)	2022-03-31
HRP20220362T1 (hr)	2022-05-13
ME03599B (me)	2020-07-20
EP3536685B1 (en)	2022-02-16
CN106458912B (zh)	2020-10-27
AR099955A1 (es)	2016-08-31
GEP20186887B (en)	2018-08-27
CU20160149A7 (es)	2017-04-05
ECSP16076566A (es)	2017-03-31
GT201600215A (es)	2018-10-19
CA2944475C (en)	2018-07-10
CL2016002524A1 (es)	2017-06-09
RS63024B1 (sr)	2022-04-29
KR101901044B1 (ko)	2018-09-20
MA39838A (fr)	2017-02-08
AP2016009514A0 (en)	2016-10-31
DK3126330T3 (en)	2019-04-23
IL248158B (en)	2018-06-28
MD4779B1 (ro)	2021-12-31
AU2015242291B2 (en)	2018-08-30
US20230339960A1 (en)	2023-10-26
BR112016023117A2 (hu)	2017-08-15
JP6177456B2 (ja)	2017-08-09
NI201600152A (es)	2016-11-18
SI3126330T1 (sl)	2019-05-31
EP3126330B1 (en)	2019-02-27
LT3536685T (lt)	2022-04-25
SV2016005295A (es)	2017-03-28
CR20160456A (es)	2016-12-01
DOP2016000271A (es)	2017-04-16
US20150284405A1 (en)	2015-10-08
TWI580678B (zh)	2017-05-01
US20160347760A1 (en)	2016-12-01
PL3536685T3 (pl)	2022-05-16
BR112016023117B1 (pt)	2023-02-07
TW201630903A (zh)	2016-09-01
UY36056A (es)	2015-10-30
ZA201606550B (en)	2018-05-30
PH12016501972A1 (en)	2016-12-19
US10793579B2 (en)	2020-10-06
CU24406B1 (es)	2019-05-03
PT3536685T (pt)	2022-03-28
TWI593683B (zh)	2017-08-01
MA39838B1 (fr)	2019-05-31
US9458168B2 (en)	2016-10-04
US10329302B2 (en)	2019-06-25
US20200377511A1 (en)	2020-12-03
JP2017206549A (ja)	2017-11-24
MX2016013052A (es)	2017-01-09
US11702424B2 (en)	2023-07-18
TWI623530B (zh)	2018-05-11
HUE057876T2 (hu)	2022-06-28
DK3536685T3 (da)	2022-03-07
US9879022B2 (en)	2018-01-30
US20190270751A1 (en)	2019-09-05
CY1125110T1 (el)	2024-02-16
SI3536685T1 (sl)	2022-05-31
EP3126330A1 (en)	2017-02-08
TW201722931A (zh)	2017-07-01
SG11201608110WA (en)	2016-10-28
ES2910128T3 (es)	2022-05-11
CY1121694T1 (el)	2020-07-31
HRP20190506T1 (hr)	2019-05-03
EA032559B1 (ru)	2019-06-28
UA121467C2 (uk)	2020-06-10
NZ724578A (en)	2019-05-31
MY192521A (en)	2022-08-25
JP2017512809A (ja)	2017-05-25
JP6492128B2 (ja)	2019-03-27
EA201600622A1 (ru)	2017-02-28
US20180127432A1 (en)	2018-05-10
AU2015242291A1 (en)	2016-10-13
MA52856A (fr)	2021-04-21
CN106458912A (zh)	2017-02-22
PT3126330T (pt)	2019-04-29
KR20160135363A (ko)	2016-11-25

Publication	Publication Date	Title
HRP20190506T1 (hr)	2019-05-03	Biciklički kondenzirani heteroarilni ili arilni spojevi i njihova upotreba kao inhibitora irak4
IL281319A (en)	2021-04-29	Amine-substituted aryl or heteroaryl compounds as EHMT1 and EHMT2 inhibitors
ZA201701501B (en)	2019-06-26	Heteroaryl compounds as btk inhibitors and uses thereof
ZA201702402B (en)	2020-07-29	Heteroaryl compounds as irak inhibitors and uses thereof
IL247057B (en)	2019-10-31	Heteroaryls inhibit syk
SG11201610904UA (en)	2017-01-27	Syk inhibitors
SG11201708027XA (en)	2017-11-29	Compounds and their use as bace1 inhibitors
EP3197885A4 (en)	2018-02-21	Heterocyclic compounds and use thereof
PT3268356T (pt)	2021-11-23	Compostos heterocíclicos e métodos para a sua utilização
GB201409661D0 (en)	2014-07-16	Novel compounds and their use as kinase inhibitors
GB201405532D0 (en)	2014-05-14	Novel compounds and their use as Kinase inhibitors
GB201413411D0 (en)	2014-09-10	Novel compounds and their use